The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...

This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...

Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...

A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...

The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...

The FDA has approved GSK’s gepotidacin (Blujepa) for treating uncomplicated urinary tract infections (uUTIs) in females aged 12 and older. The approval is based on successful phase 3 EAGLE-2 ...

The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract infections (UTIs) in nearly 30 years. More than half of all women ...

For the longest the only treatment available for an uncomplicated UTI was nitrofurantoin. But now, FDA has approved Blujepa, another drug that can treat it. Read on to know more.

The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be available in the second half of 2025. Blujepa is approved to treat females 12 and older with uncomplicated ...

The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, GSK announced.